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Background: Müllerian aplasia (MA) is a congenital disorder of the female reproductive tract with absence of
uterus and vagina with paramount impact on a woman’s life. Despite intense research, no major genes have been
found to explain the complex genetic etiology.
Methods and Results: We have used several genetic methods to study 112 patients with MA. aCGH identified
CNVs in 8/50 patients (16%), including 16p11.2 and 17q12 deletions previously associated with MA. Subsequently,
another four patients were shown to carry the ~0.53 Mb deletion in 16p11.2. More importantly, sequencing of TBX6,
residing within 16p11.2, revealed two patients carrying a splice site mutation. Two previously reported TBX6 variants
in exon 4 and 6 were shown to have a significantly higher frequency in patients (8% and 5%, respectively) than in
controls (2% each). We also sequenced LHX1 and found three apparently pathogenic missense variants in 5/112
patients. Altogether, we identified either CNVs or variations in TBX6 or LHX1 in 30/112 (26.8%) MA patients. CNVs
were found in 12/112 (10.7%), patients, novel variants in TBX6 or LHX1 in 7/112 (6.3%), and rare variants in TBX6 in
15/112 (13.4%) patients. Furthermore, four of our patients (4/112, 3.6%) were shown to carry variants in both TBX6
and LHX1 or a CNV in combination with TBX6 variants lending support to the complex genetic etiology of MA.
Conclusions: We have identified TBX6 as a new gene associated with MA. Our results also support the relevance of
LHX1 and CNVs in the development of this congenital malformation.Background
Müllerian aplasia (MA) is a rare disorder of the female re-
productive tract presenting as congenital loss of a func-
tional uterus and vagina. MA is commonly diagnosed in
adolescent females due to lack of menstruation and has a
large impact on a woman’s life. Inability of normal sex life
prior to treatment and infertility combined with psycho-
social problems make it one of the difficult fertility disor-
ders diagnosed in young females. MA is also referred to as
MURCS association (Müllerian duct aplasia, Renal dyspla-
sia and Cervical Somite anomalies [MIM 601076]), be-
cause renal and skeletal malformations are associated with
the disorder. Despite MA, the patients have a normal fe-
male karyotype and secondary sexual characteristics [1].* Correspondence: kristiina.aittomaki@hus.fi
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distribution, and reproduction in any mediumThe incidence is estimated to be at least one in 5000
according to a population-based study in Finland [2].
During vertebrate embryogenesis, the female repro-
ductive tract forms as a part of the urogenital system de-
rived from the intermediate mesoderm of the developing
embryo. The urogenital system encompasses the kid-
neys, gonads and the urinary and reproductive tracts.
The female reproductive tract primarily develops from
the Müllerian ducts (MD), which form as an invagin-
ation of the coelomic epithelium and further develop
into the upper two-thirds of the vagina, the uterus and
the Fallopian tubes [3,4].
Most patients with MA have the Mayer-Rokitansky-
Küster-Hauser (MRKH [MIM 277000]) phenotype with
presence of small remnants of the uterus and with uni-
lateral/bilateral Fallopian tubes. A small group of pa-
tients are reported with complete loss of Müllerian
derivatives, called total Müllerian aplasia [1,2].
The genetic background of MA has been intensively
studied. The anti-Müllerian hormone (AMH), essentialtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tor AMHR2 and members of the HOXA and WNT gene
families were primarily investigated in MA patients, but
no mutations were found [5-12]. More recently muta-
tions in wingless-type MMTV integration site family,
member 4 (WNT4) and the LIM homeobox 1 (LHX1),
have been reported to be causative of MA [13-18]. How-
ever, WNT4 defects occur in MA patients with
hyperandrogenism not usually associated with the syn-
drome [13-16]. The LHX1 defects were reported in pa-
tients with MRKH, the major clinical phenotype of MA,
but only in two cases thus far [17,18]. The mutant
mouse model for LHX1 (Lim1−/−) lacks uterus and ovi-
ducts, but has normal ovaries coinciding with MA
phenotype in humans [19]. Recent mutation screening
efforts in a small number of MA patients in other genes
involved in the development of the MD, namely RARG,
RXRA [20], CTNNB1 [21], PBX1 [22], PAX2 [23],
DLGH1 and LAMC1 [24] have all been negative. The
cause of MA is therefore still unknown for the vast ma-
jority of the patients.
By copy number analysis, several candidate regions
have been implicated in MA [17,20,25-29]. Of these,
most promising are regions on 16p11.2 and 17q12. The
17q12 region includes LHX1and another candidate gene,
HNF1B. HNF1B has been associated with genital
malformations, diabetes and renal cysts [30], but no mu-
tations in MA patients have been identified to date [28],
[18]. In the 16p11.2 region, deletions were recently
reported in four patients with MA [29]. Deletions in this
region have previously been associated with autism
[31,32], developmental delay [33] and obesity [34], while
duplications have been associated with autism [32], de-
velopmental delay [33] and schizophrenia [35]. The re-
gion includes approximately 26 genes with at least one
gene with known function in mesodermal development,
the T-box gene TBX6 [36]. Here, we report results of
CNV analysis and screening of TBX6 and LHX1 in 112
patients with MA, and suggest a role also for TBX6 in
the complex genetics of MA, and therefore in the devel-
opment of the female reproductive system.Patients and methods
One-hundred and ten Finnish and two foreign patients
originating from Russia and Middle East with a well-
characterized MA phenotype were recruited to the study
as previously described [37]. The patients had not been
found to have symptoms or features of other syndromes.
Two-hundred women with at least one normal pregnancy
served as controls. Informed consent was obtained from
all patients and controls before recruitment. The study
protocol has been approved by the Ethics Committee of
the Department of Obstetrics and Gynecology, HelsinkiUniversity Central Hospital, Finland, and the Finnish
Ministry of Social Affairs and Health.
Sample preparation
DNA from the patients and controls was extracted from
peripheral blood samples using the Puregene DNA Isola-
tion Kit (Gentra Systems, Minneapolis, MN, USA), or by
the phenol-chloroform method. The quality and quantity
of DNA was analyzed by NanoDrop ND-1000 spectro-
photometer (Thermo Fisher Scientific, Waltham, MA,
USA).
Array Comparative Genomic Hybridization (aCGH)
Fifty Finnish patients, in whom detailed phenotypic data
had been obtained by laparoscopy, were selected for the
aCGH analysis, which was performed on a 180 K plat-
form (Oxford Gene Technology, Yarnton, Oxford, UK).
Briefly, samples were labeled with Cy3-and Cy5-
deoxycytidine triphosphates by random priming. Purifi-
cation, hybridization and washing were carried out as
recommended by the manufacturer. Scanned images of
the arrays were processed using Feature Extraction soft-
ware (Agilent Technologies, Santa Clara, CA, USA).
Genomic Workbench software (Agilent Technologies)
was used for calling DNA copy number variations
(CNVs) using the aberration detection statistical algo-
rithm ADM-2, and sensitivity threshold 6.7. Duplication
or deletion of a genomic segment was considered, when
the log2 ratio of the Test/Reference intensities of a given
region encompassing at least three probes was > 0.3 or
< −0.3, respectively. Detected CNVs were compared to
CNV data documented in the Database of Genomic Var-
iants (DGV) [38].
Multiplex ligation-dependent probe amplification (MLPA)
The MLPA method was used to study the 112 patients
for larger deletions or duplications within TBX6. One
hundred control samples were also investigated with the
method. Synthetic MLPA probes (Additional file 1:
Table S1) covering each of the coding exons of TBX6
(exons 2–9, TBX6-001 transcript, Ensembl genome
database hg19/GRCh37) [39], the non-coding exon 1,
the 3’ UTR region and a presumptive TBX6 promotor
region upstream of exon 1 identified by CpG Plot [40]
and CpG Island Searcher [41] were designed according
to the manual Designing synthetic MLPA Probes
(MRC-Holland, Amsterdam, the Netherlands). The spe-
cificity of the probe sequences were checked using the
UCSC Genome Browser (GRCh37/hg19) [42], the RaW-
Probe Version 0.15β program [43] and Mfold [44]. To
enable even spreading of the probe sizes and compatibil-
ity with the P300 Human reference probemix (MRC-
Holland), the lengths of nine of the eleven probes were
adjusted using non-hybridizing stuffer fragments. The
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primers and a stuffer sequence were designed to range
between 96 bp and 136 bp (IDT, San Jose, CA, USA).
The MLPA reactions were performed according to the
manufacturer’s recommendations. In short, 200 ng of
DNA was denatured and incubated with a mix including
1 μM of each of MLPA synthetic oligos and the P300
Human reference probemix for 16–18 h in 60°C. The
probes were ligated to the DNA and amplified by PCR.
Thereafter, the PCR products were visualized on an
agarose gel (1.5%, Bioline, London, UK), appropriately
diluted and combined with 1% formamide (Applied
Biosystems) and GeneScan™-500 LIZ™ size standard (Ap-
plied Biosystems). The products were separated by capil-
lary electrophoresis on an ABI3730XL DNA Analyzer
(Applied Biosystems). The results were analyzed by
GeneMapper software version 4.0 (Applied Biosystems)
and verified by the following calculation. For each sam-
ple, each peak area was divided by the sum of all peak
areas (derived from the 11 synthetic TBX6 probe areas
plus the 17 reference peak areas from the P300 Human
reference probemix). Each quotient was further divided
by the peak area of the reference sample. A result ≤0.7
or ≥1.3 was taken as suggestive for a deletion or duplica-
tion, respectively. All aberrant results were confirmed by
a second independent MLPA analysis and deletions of
the entire gene with SNP genotyping.
Validation of aCGH and MLPA findings
High-throughput genotyping was performed using the
Human Omni2.5-8 BeadChip v1.0 (Illumina, San Diego,
CA, USA) capturing about 2.4 million markers to con-
firm the genomic alterations found by aCGH and MLPA.
Data analyses were performed using GenomeStudio
V2011.1 (Illumina). In addition, quantitative PCR
(qPCR) was used to confirm six of the deletions and du-
plications detected by aCGH using the SYBR Green sys-
tem (Roche Applied Science, Indianapolis, IN, USA) on
a 7500 Fast Real-Time PCR System apparatus (Applied
Biosystems, Foster City, CA, USA). We used six of the
healthy Finnish female controls for copy number calibra-
tion, and the qPCR values for the GAPDH and HPRT for
normalization. All samples were run in triplicate, and
the data was analyzed with Microsoft Excel software
(Microsoft Corp, Redmond, WA, USA) using the
comparative ΔΔC t cycle threshold method (Applied
Biosystems), which assumes that the calibrator DNA has
two copies of the control genes.
PCR and Sanger sequencing
The coding exons and exon-intron boundaries of TBX6
(exons 2–9, TBX6-001 transcript, Ensemble genome
database hg19/GRCh37) [39] were studied in 112 pa-
tients and 200 controls by Sanger sequencing. The PCRprimers were designed using ExonPrimer [45] and
Primer3 v. 0.4.0 [46]. The PCR was performed under
standard conditions. The products were visualized by gel
electrophoresis and subjected to sequencing in an
ABI3730xl DNA Analyzer (Applied Biosystems) and an-
alyzed by Sequencher 5.0 (Gene Codes, Ann Arbor, MI,
USA). Likewise, all coding exons and exon-intron
boundaries of LHX1 (exons 1–5, LHX1-001 transcript,
Ensemble genome database hg19/GRCh37) [39] were
studied in the patients and 150 controls using primers
designed by Primer3 v. 0.4.0 [46] and standard PCR re-
actions. Variants in the coding region of LHX1 were se-
quenced in altogether 180 controls.
RT-PCR
Peripheral blood was drawn from three patients and three
controls using the PAXgene Blood RNA Tube (Pre-
AnalytiX Gmbh, Hombrechtikon, Switzerland) and RNA
was subsequently extracted by the PAXGene RNA Kit
(Qiagen, Hilden, Germany) according to the recommended
protocol. The extracted RNA was further treated with
DNA-free kit (Applied Biosystems) to remove genomic
DNA (gDNA). cDNA synthesis was done using High
capacity cDNA reverse transcriptase kit (Applied
Biosystems) in a final volume of 20 μl according to the
manufacturer’s recommendations. RT-PCR was performed
using DreamTaq PCR master mix (2x) (Thermo Scientific,
Walthem, MA, USA), primers designed for exon 4 (5’
TACATTCACCCCGACTCTCC 3’) and exon 6 (5’
TGGCTGCAATCTTCAGTTGT 3’) by Primer3 v. 0.4.0
[46] and a touchdown thermocycling PCR program with
annealing temperatures from 67°C to 55°C and the prod-
ucts were visualized by gel electrophoresis.
Statistics
Differences in SNP allele frequency between patients
and controls were calculated using the non-parametric
Mann–Whitney-U test (PASW Statistics 18, SPSS,
Chicago, IL, USA) using Bonferroni correction for mul-
tiple testing.
Prediction programs
In silico analyses of genomic variants were performed
using MutationTaster [47], PON-P [48] including PhD-
SNP 2.0.6, PolyPhen 2.0.22, SIFT 4.0.3, SNAP 1.0.8 and
I-Mutant 3.0.6 programs used for analysis, SpliceMan
[49], SplicePort [50] and Human Splicing Finder [51]
software programs.
Results
Initially, we chose 50 patients for copy number analysis
using aCGH and identified nine CNVs in eight (16%) of
them (Table 1). Two of the identified CNVs have been
previously reported in MA, namely deletions on 16p11.2
Table 1 Summary of aCGH results
Locus Patient
ID
Size CNV Location Genes within CNV Confirmation
method
5p14.3 28 1.6 Mb Del 5:18822021-
20417776
CDH18 SNP array,
qPCR
9q21.13 3 95 Kb Del 9:74296070-
74391713
TMEM2 SNP array
11q13.4 2 54 Kb Del 11:73584463-
73638725
CHCHD8, PAAF1 SNP array,
qPCR
15q26.1 4 96 Kb Del 15:90883372-
90979449
ZNF774, IQGAP1 SNP array,
qPCR
16p11.2 69 0.53 Mb Del 16:29656457–
30190734
SPN, QPRT, C16orf54, MAZ, PRRT2, C16orf53, MVP, CDIPT, LOC440356, SEZ6L2, ASPHD1, KCTD13, TMEM219, TAOK2, HIRIP3,
INO80E, DOC2A, C16orf92, FAM57B, ALDOA, PPP4C, TBX6, YPEL3, GDPD3, MAPK3, LOC100271831
SNP array
16p13.3 42 143 Kb Del 16:6213403-
6356820
A2BP1 SNP array,
qPCR
17q12 24 1.7 Mb Del 17:31584620-
33353268a
TBC1D3C, CCL3L1, CCL3L3, CCL4L2, CCL4L1, TBC1D3H, TBC1D3C, TBC1D3G, ZNHIT3, MYO19, PIGW, GGNBP2, DHRS11, MRM1,
LHX1, AATF, ACACA, C17orf78, TADA2L, DUSP14, AP1GBP1, DDX52, HNF1B, LOC284100
SNP array
19q13.11b 49 194 Kb Dupl 19:33532490-
33727077
RHPN2, GPATCH1, WDR88, LRP3, SLC7A10 SNP array,
qPCR
19q13.12b 49 0.6 Mb Dupl 19:35731695-
36309487
LSR, USF2, HAMP, MAG, CD22, FFAR1, FFAR3, FFAR2, KRTDAP, DMKN, SBSN, GAPDHS, TMEM147, ATP4A, HAUS5, RBM42, ETV2,
COX6B1, UPK1A, ZBTB32, MLL4, TMEM149, U2AF1L4, PSENEN, LIN37, HSPB6, C19orf55, SNX26, PRODH2
SNP array,
qPCR
alocation according to UCSC genome database hg18.
blikely to include non-duplicated regions, possibly due to other chromosomal rearrangements e.g. inversions within the region or non-functional aCGH probes.
CNV = copy number variations, Del = deletion, Dupl = duplication.
Location according to UCSC genome database hg19 [42].
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ther investigate two interesting MA candidate genes
within these two regions, namely TBX6 and LHX1.
DNA from 112 MA patients was Sanger sequenced for
the entire coding region and the exon-intron boundaries
of TBX6 (exons 2–9, RefSeq NM_004608.3). We found a
novel heterozygous splice site mutation c.622-2A>T
(g.30100162 T>A) in two patients (Figure 1). The
mutation was not found by sequencing 200 Finnish
healthy females, in dbSNP [52], in 1000 Genomes
database [53], or in cohort data comprising of 1532
alleles of Finnish ancestry (A-P Sarin and A. Palotie,
personal communication). In Exome Variant Server
(EVS, [February, 2013 accessed]) [54], where >12000
alleles of African American and European American
ancestry have been sequenced for TBX6, no allele with
this variant was reported.
The mutation (c.622-2A>T) is situated in the canon-
ical sequence of the highly conserved splice acceptor site
(AG) for exon 5 (Figure 2). MutationTaster [47],
SplicePort [50] and Human Splicing Finder [51] predic-
tion programs all indicate that the mutation causes loss
of the functional acceptor site while the SpliceMan pre-
dictor program [49] gives a prediction score of 69% for
the likelihood of the mutation to disrupt splicing. The
loss of the splice acceptor site is likely to result in skip-
ping of exon 5 or the use of cryptic splice sites. The
c.622-2A>T mutation resides within the highly con-
served DNA-binding domain, the T-box, of the protein
(aa 100–273, encoded from the 3’end of exon 3 to the 3’Figure 1 Novel splice site mutation of TBX6 in two MA patients. Splice
compared to healthy control sample (on the top). The mutation is indicateend of exon 6) (Figure 2). RT-PCR revealed presence of
at least three different transcripts ranging from about
270 to 480 kb in size, all present in both patient and
control samples.
In addition, we found six TBX6 variants, all previously
reported in dbSNP [52] (Table 2). Noteworthy is that
the exonic missense variants in exon 4 (rs56098093;
g.30100401C>T; p.Gly162Ser) and exon 6 (rs201231713;
g.30099890C>T; p.Arg272Gln) were found in a higher
frequency in patients compared to healthy females. The
minor allele frequency (MAF) for rs56098093 was 8.0%
for the patients and 2% for the controls and MAF for
rs201231713 was 5.8% for the patients and 2% for the
controls. The differences were statistically significant
(P-value 0.0021 for rs56098093 and 0.0002 for
rs201231713), after a stringent Bonferroni correction for
multiple testing (P-value / 2 < 0.05). Interestingly, two
Finnish MA patients were homozygous for both variants
(AA and AA, respectively) while none of the 200
sequenced controls were homozygous for either of the
variants. In the Finnish cohort data of 1532 alleles, the
frequencies of the variants were 0.5% (exon 4) and 0.7%
(exon 6), respectively (A-P Sarin and A. Palotie, personal
communication). Both variants are situated within the
highly conserved DNA-binding T-box region of the gene
(Figure 2). MutationTaster [47] predicts both variants as
disease causing with loss of the DNA-binding region of
the gene. PON-P [48] predicts both variants as patho-
genic with a probability of pathogenicity scores of 0.81
(Gly162Ser) and 1 (Arg272Gln), respectively.site mutation c.622-2A>T (g.30100162 T>A) in two MA patients
d by an arrow.
TBX6-001 transcript
NM_004608.3
1803 bp
NP_004599.2
436 aa
98765432exon 
reverse strand
T-box (aa 100-273)
6.09 Kb
Homo sapiens
Mus musculus
Rattus norvegicus
Pan troglodytes
Pongo pygmaeus
Gorilla gorilla
splice
site
rs56098093 rs201231713
cct ccc a g CTG ATC
cct ccc a g CTG ATC
cct ccc a g CTG ATC
cct ccc a g CTG ATC
cct ccc a g CTG ATC
cct ccc a g CTG ATC
Figure 2 Schematic view of TBX6. A schematic view of TBX6 on genomic and protein level with indication of rare variants (rs56098093 and
rs201231713) and the splice site mutation site (g.30100162 T>A, c.622-2A>T in violet brackets and a line) and its conservation among species.
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of the entire TBX6 in five out of 112 (4.5%) patients, in-
cluding the patient with 16p11.2 deletion found by
aCGH (Figure 3). The peak area-based calculations indi-
cated that these patients have a loss of one copy for all
eleven TBX6 probes (value approximately 0.7) compared
to the reference with two gene copies (value 1.0) and to
the 100 healthy female controls. To delineate further the
nine CNVs found by aCGH and the TBX6 deletions
found by MLPA, these patients were also studied by
SNP genotyping (HumanOmni2.5-8, Illumina). The het-
erozygous TBX6 deletions found by MLPA were shown
to embrace not only TBX6, but the same 0.53 Kb dele-
tion on 16p11.2, which was initially detected by aCGH
in patient 69, in all five patients (Figure 4).
By sequencing the entire coding region and the exon-
intron boundaries of LHX1, we found altogether five
patients with novel variants in the gene (Figure 5). One
patient had a missense variant (g.35295505G>C; p.
Cys4Ser) in exon 1, three patients had the same mis-
sense variant in ex 5 (g.35300142C>A; p.Pro312His) and
one patient had another missense variant in ex 5
(g.35300202C>G; p.Arg332Pro) (Table 3). None of the
variants are reported in dbSNP [52], 1000 Genomes
database [53] or EVS, except Arg332Pro, which was
found in 1/12783 alleles in EVS. MutationTaster [47]
predicts all three missense variants as disease causing.
The program predicts the Cys4Ser variant to cause loss
of the LIM zinc-binding 1 domain (aa 4–54) of the gene.
PON-P [48] predicts Cys4Ser as unclassified with a
probability of pathogenicity score 0.75, Pro312His andArg332Pro as neutral with probability of pathogenicity
scores of 0.03 and 0.01, respectively.
A flow chart summarizing the main results and
methods is shown in Figure 6.
Discussion
We report here the results of genetic studies on
Müllerian aplasia, namely, results of TBX6 and LHX1
mutation screening in 112 MA patients and CNV ana-
lysis in a subset of them.
Sequencing of TBX6 (located in 16p11.2) revealed a
splice mutation in two patients and rare missense vari-
ants in 15 patients (13.4%). TBX6 is a transcription
factor that functions in early embryogenesis. It resides
on the minus strand with a full-length transcript
of 1806 bp, encoding a 436 aminoacid protein
(NP_004599.2). TBX6 is a member of a phylogenetically
well-conserved T-box gene family, where all members
share the similar N-terminal DNA-binding domain, the
T-box [55]. We identified a c.622-2A>T splice site muta-
tion in two patients (one with MRKH and the other with
total MA and with ovarian aplasia) and a rare homozy-
gous missense variant in exon 4 and exon 6 in two pa-
tients. The splice site mutation is situated in the highly
conserved splice acceptor site (AG) of exon 5. According
to the in silico prediction programs, the mutation is
likely to decrease correct splicing of exon 5, which is lo-
cated in the highly conserved DNA-binding T-box, or
result in use of cryptic splice sites. To investigate the
consequences of this mutation on mRNA level, we
extracted RNA from whole blood, which was available
Table 2 Variants of TBX6 with allele frequencies
Varianta rs numberb Location in TBX6 Genotype of patientsc Genotype of controlsc
Predicted change N=112 N=200
g.30102391G>A rs112565029 intron 2 CC: 107 (95.5%) CC: 187 (93.5%)
c.118+6C>T CT: 5 (4.5%) CT: 13 (6.5%)
TT: 0 (0%) TT: 0 (0%)
g.30100402G>A rs147485102 exon 4 CC: 111 (99.1%) CC: 198 (99%)
p.Ser161= CT: 1 (0.9%) CT: 2 (1%)
TT: 0 (0%) TT: 0 (0%)
g.30100401C>T rs56098093 exon 4 GG: 97 (86.6%) GG: 192 (96%)
p.Gly162Ser GA: 12 (10.7%) GA: 8 (4%)
AA: 3 (2.7%) AA: 0 (0%)
g.30100162 T>A - intron 4 AA: 11 (98.2%) AA: 200 (100%)
c.622-2A>T AT: 2 (1.8%) AT: 0 (0%)
TT: 0 (0%) TT: 0 (0%)
g.30099890C>T rs201231713 exon 6 GG: 101 (90.2%) GG: 198 (99%)
p.Arg272Gln GA: 9 (8.0%) GA: 2 (1%)
AA: 2 (1.8%) AA: 0 (0%)
g.30098022G>A rs200310768 intron 7 CC: 109 (97.3%) CC: 194 (97%)
c.914-6C>T CT: 3 (2.7%) CT: 6 (3%)
TT: 0 (0%) TT: 0 (0%)
g.30097630C>T rs2289292 exon 9 GG: 32 (28.6%) GG: 67 (33.5%)
p.Pro409= GA: 55 (49.1%) GA: 95 (47.5%)
AA: 25 (22.3%) AA: 38 (19%)
The splice site mutation and the rare variants indicated in bold.
avariations presented according to genomic reference sequence (g.) NC_000016.9, coding DNA reference sequence (c.) NM_004608.3 and/or protein reference
sequence (p.) NP_004599.2, Genome Build 37.3, dbSNP [52].
brs numbers for previously known SNPs according to dbSNP [52].
cnumber of genotypes reported as: reference allele/reference allele; reference allele/alternative allele; alternative allele/alternative allele.
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products were obtained, indicating that several mRNA
transcripts are present, but the sizes of the products did
not differ in patient and control samples. The reason for
this is most likely that very little or none of the mutated
transcript is transcribed. Two patients were homozygous
for both the exon 4 and the exon 6 variant of TBX6, ten
patients were heterozygous for both, and three patients
had the exon 4 variant in a heterozygous state. Both var-
iants are situated within the conserved T-box region and
the prediction programs indicate that the variants have
an effect also on the protein level. We therefore believe
that these variants together with other variations have a
role in the multifactorial etiology of MA. However, to fi-
nally determine the nature of the TBX6 splice site muta-
tion and of the rare homozygous variants in ex 4 and 6
of the gene, in vitro functional studies are needed.
TBX6 has been suggested to associate with congenital
scoliosis in the Chinese Han population [56]. Interest-
ingly, vertebral changes giving rise to e.g. scoliosis, arecommonly found in patients with MA. Recently, a mis-
sense mutation in the last codon of the TBX6 transcript
was observed in a Macedonian family with the auto-
somal dominant form of spondylocostal dysostosis
(SCD), characterized by segmentation defects of the ver-
tebrae [57]. The affected individuals were all males and
therefore there is no data about the effect of the TBX6
mutation on the development of the female urogenital
tract. The family had also experienced six infant deaths
(one girl, five boys) of unknown cause without further
phenotype data [57,58]. Mouse knock-out studies have
shown that Tbx6 is important for segmentation of the
somites in the paraxial mesoderm [59] and for left/right
patterning [60]. White and coworkers have shown that
Tbx6 interacts with the Notch-ligand delta-like 1 (Dll1)
[36], a component in the Notch pathway. Also WNT sig-
naling, acting upstream of Tbx6, has been shown to
regulate Dll1 activity [61]. Both Notch and WNT signal-
ling are import in the so called segmentation clock, cyc-
lic expression of genes under which each somite is
Figure 3 Detection of TBX6 deletions by multiplex ligation probe amplification (MLPA). A ~30% reduction in peak size of the TBX6-specific
probes in patient (above) compared to control sample (below). Each exon of TBX6 is indicated by its corresponding number (in bold),
prom = promotor, 3’UTR = 3’untranscribed region, D =a quality control fragment, and R=four reference probes.
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http://www.ojrd.com/content/8/1/125formed from the presomitic mesoderm [62]. It is con-
ceivable that a similar segmentation clock could operate
in the segmentation of Müllerian ducts to form upper
vagina, uterus and Fallopian tubes.
A spontaneous mouse model for Tbx6 is the homozy-
gous Tbx6rv (rib-vertebrae). It is caused by an insertionFigure 4 SNP array genotyping confirming the 16p11.2 deletion. Five
HumanOmni2.5-8 v1.0, Illumina. The patient samples are here shown toget
V2011.1, Illumina).in the Tbx6 promotor upstream of the transcriptional
start site resulting in a hypomorphic allele and reduced
transcript expression [63]. The mutation affects somite
formation and patterning featured as malformations of
the axial skeleton and fusions of adjacent segments.
Interestingly, the model also shows malformations in theMA patients were confirmed with the 16p11.2 deletion using
her with a normal control sample (Genome Viewer, GenomeStudio
Figure 5 Three novel LHX1 variants found in five MA patients. Three novel LHX1 missense variants found in five MA patients. A) The
g.35295505G>C (p.Cys4Ser) variant in control and patient 223, B) the g.35300142C>A (p.Pro312His) in control and patients 162, 237, and 97 and
C) the g.35300202C>G (p.Arg332Pro) in control and patient 110. The variations are indicated by arrows.
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Table 3 Variants of LHX1 with allele frequencies
Varianta rs numberb Location in LHX1 Genotype of patientsd Genotype of controlsd
Predicted change N=112 N= 180
g.35295505G>C - exon 1 GG: 111 (99.1%) GG: 180 (100%)
p.Cys4Ser GC: 1 (0.9%) GC: 0 (0%)
CC: 0 (0%) CC: 0 (0%)
g.35300142C>A - exon 5 CC: 109 (97.3%) CC: 180 (100%)
p.Pro312His CA: 3 (2.7%) CA: 0 (0%)
AA: 0 (0%) AA: 0 (0%)
g.35300202C>G TMP_ESP_17_35300202c exon 5 CC: 111 (99.1%) CC: 180 (100%)
p.Arg332Pro CG: 1 (0.9%) CG: 0 (0%)
GG: 0 (0%) GG: 0 (0%)
avariations presented according to genomic reference sequence (g.) NC_000017.10, coding DNA reference sequence (c.) NM_005568.3 and/or protein reference
sequence (p.) NP_005559.2, Genome Build 37.3, dbSNP [52].
brs numbers for previously known SNPs according to dbSNP [52] or Exome Variant Server (EVS) [54].
cone allele of 12783 reported in EVS [54].
dnumber of genotypes reported as: reference allele/reference allele; reference allele/alternative allele; alternative allele/alternative allele.
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http://www.ojrd.com/content/8/1/125renal and urinary system e.g. with reported single kidney
and in the reproductive system with reduced female fer-
tility. Unfortunately, no detailed information is available
on the status of the reproductive tract or on why the fe-
male mice are reported as poor breeders [64]. However,
the Tbx6rv has phenotypic similarities with MURCS, as
the phenotype includes skeletal and renal malformations.
In addition, if the reduced fertility is caused by defectsDNA samples from
N=112
aCGH
N=50
Patients with CNVs
N=8a (16 %)
Patients with TBX6 deleti
N=5a (4.5%)
SNP genotyping
N=12
Patients investigated for CNVs, N=54
Figure 6 Flow chart summarizing main results and methods. A flow ch
including number of patient samples investigated by each of the methodsin the reproductive tract, the mouse model would be of
interest for functional studies in MA.
Previous candidate gene studies of LHX1 residing in
the 17q12 deletion region revealed two MA patients
with heterozygous mutations [17,18]. The gene had been
suggested as a strong candidate for mutation screening
based on studies in mice [19] showing that lim1, which
is 99.5% homologous to the human LHX1 gene [65], is MA patients
Candidate gene screening
N=112
ons
Patients with
TBX6 variants
novel, N=2 (1.8 %)
rare, N=15 (13.4 %)
Patients with
LHX1 variants
novel,
N=5 (4.5%)
a
 patient 69 included in both sample series
art summarizing the main results and methods used in the study,
.
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duct during its formation. Female lim1-null mice present
normal ovaries but completely lack all derivatives of the
Müllerian ducts (oviducts, uterus, cervix and the upper
region of the vagina), thereby resembling the total MA
phenotype. Therefore, we performed sequencing of
LHX1 in our patient cohort and found three novel mis-
sense variants in five MA patients (four Finnish and one
foreign). The in silico prediction programs indicate that
the exon 1 variant is deleterious, while the data for the
other two are discrepant. Further studies are needed to
define their role in the development of MA. The patient
with the exon 1 variant (Cys4Ser) had total MA. Inter-
estingly, one patient with the exon 5 variant (Pro312His)
was also homozygous for both rare TBX6 variants
(rs56098093 and rs201231713). Another patient with the
same LHX1 exon 5 variant was heterozygous for both
rare TBX6 variants. Furthermore, the other patient
homozygous for both rare TBX6 variants was also identi-
fied with a 11q13.4 deletion.
We also identified nine different CNVs in 12 patients
(10.7%) using aCGH and SNP genotyping. Seven of the
CNVs are novel (five deletions found in one patient each
and two duplications found in the same patient)
reported here for the first time in association with MA,
and have not been documented in normal controls
(DGV) [38]. Nevertheless, we cannot conclude if they
have a role in the development of MA. However, the
genes located within these CNVs are possible candidate
genes for further studies. Two CNVs, namely deletions
in 16p11.2 and 17q12, have previously been described in
four [29] and eight [17,27-29] MA patients, respectively.
We found the 16p11.2 deletion in five patients and the
17q12 deletion in one patient, adding the total number
of MA patients to nine for both deletions. Although the
number of patients identified with the deletions is low,
they have to date been identified in MA patients origin-
ating in two and five different populations, respectively,
and therefore they are likely to be relevant for the devel-
opment of MA.
The 16p11.2 region is prone to rearrangements and
CNVs in the region have previously been associated with
different clinical phenotypes [31-33,66], [35], [34].
Bijlsma and coworkers sequenced the coding regions of
ALDOA, TBX6 and SPN in four patients with 16p11.2
deletion and mild mental retardation. No mutations
were found and they concluded that CNVs of 16p11.2
are associated with variable phenotypes [67]. In our
study, five MA patients showed the deletion. Three of
these had skeletal findings including scoliosis and minor
vertebral defects, which are known symptoms of MA. In
addition, one patient had an unexplained weight gain of
32 kg within 2 years and another had experienced sei-
zures of unknown cause. Because the 16p11.2 region islarge and includes many genes, it is reasonable to as-
sume that several phenotypes, including MA, may be as-
sociated with this deletion.
Conclusions
Taken together, our findings suggest that both TBX6 and
LHX1 participate in the control of the development of
the female reproductive tract. While the number of mu-
tations so far identified in these two genes is low, more
mutations are likely to be found when extending the
mutation screening to other populations and to embrace
the promotor regions, intronic sequences and the 5’ and
3’ UTR regions of the genes. Our results also strengthen
the previous finding that deletions in 16p11.2 and 17q12
are associated with MA. Furthermore, the results sup-
port the hypothesis that MA indeed is a complex trait as
demonstrated by the finding that four of our patients
were shown to carry variants in both TBX6 and LHX1 or
a CNV in combination with TBX6 variants. While our
findings on TBX6 need to be confirmed in independent
patient cohorts, it is equally important that further genes
in the deleted regions are studied for an association with
MA. Likewise, functional studies of the identified genes
will enhance the understanding of how the Müllerian
derivatives are formed during normal embryogenesis
and how and why the development is disrupted to result
in Müllerian agenesis, the congenital abnormality, which
so profoundly affects the life of young females.
Additional file
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